In vivo therapeutic evaluation of the gene therapy strategy with FIX pDNA-encapsulated Gal-LNC in a transgenic animal model with factor IX knock-out (hemophilia B mouse model) must be performed to complete the pre-clinical evaluations. This evidence concerns the gene F9 and hemophilia B.